Journal of Affective Disorders
Volume 90, Issue 1 , Pages 83-89 , January 2006

Lower cerebrospinal fluid homovanillic acid levels in depressed suicide attempters

  • Leo Sher

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Suite 2917, Box 42, New York, NY 10032, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 543 6240; fax: +1 212 543 6017.
    • ,
  • J. John Mann

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Suite 2917, Box 42, New York, NY 10032, USA
    • ,
  • Lil Traskman-Bendz

      Affiliations

    • Department of Psychiatry, University of Lund, Lund, Sweden
    • ,
  • Ronald Winchel

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Suite 2917, Box 42, New York, NY 10032, USA
    • ,
  • Yung-yu Huang

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Suite 2917, Box 42, New York, NY 10032, USA
    • ,
  • Eric Fertuck

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Suite 2917, Box 42, New York, NY 10032, USA
    • ,
  • Barbara H. Stanley

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Suite 2917, Box 42, New York, NY 10032, USA

Received 28 July 2005 ,Revised 6 October 2005 ,Accepted 10 October 2005.

References 

  1. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol. Psychiatry. 2004;55:1001–1006
  2. Agren H. Life at risk: markers of suicidality in depression. Psychiatr. Dev. 1983;1:87–103
  3. Arranz B, Blennow K, Eriksson A, Mansson JE, Marcusson J. Serotonergic, noradrenergic, and dopaminergic measures in suicide brains. Biol. Psychiatry. 1997;41:1000–1009
  4. Asberg M, Bertilsson L, Martensson B, Scalia-Tomba G-P, Thoren P, Traskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatr. Scand. 1984;69:201–219
  5. Bachus SE, Hyde TM, Akil M, Weickert CS, Vawter MP, Kleinman JE. Neuropathology of suicide. A review and an approach. Ann. N.Y. Acad. Sci. 1997;836:201–219
  6. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961;4:53–63
  7. Beck RW, Morris JB, Beck AT. Cross-validation of the Suicidal Intent Scale. Psychol. Rep. 1974;34:445–446
  8. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J. Consult. Clin. Psychol. 1974;42:861–865
  9. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J. Consult. Clin. Psychol. 1979;47:343–352
  10. Bergquist J, Traskman-Bendz L, Lindstrom MB, Ekman R. Suicide-attempters having immunoglobulin G with affinity for dopamine in cerebrospinal fluid. Eur. Neuropsychopharmacol. 2002;12:153–158
  11. Berrettini WH, Nurnberger JI, Narrow W, Simmons-Alling S, Gershon ES. Cerebrospinal fluid studies of bipolar patients with and without a history of suicide attempts. Ann. N.Y. Acad. Sci. 1986;487:197–201
  12. Blennow K, Wallin A, Gottfries CG, Mansson JE, Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J. Neural Transm., Parkinson's Dis. Dement. Sect. 1993;5:5–15
  13. Blum K, Braverman ER, Wu S, Cull JG, Chen TJ, Gill J, et al. Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Mol. Psychiatry. 1997;2:239–246
  14. Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res. 1997;769:135–140
  15. Brown GL, Goodwin FK. Human aggression and suicide. Suicide Life-Threat. Behav. 1986;16:223–243
  16. Buss AH, Durkee A. An inventory for assessing different kinds of hostility. J. Consult. Psychol. 1957;21:343–349
  17. Coccaro E. Neurotransmitter function in personality disorders. In:  Silk KR editors. Biology of Personality Disorder. Washington, DC: American Psychiatric Press; 1998;p. 125
  18. Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J. Clin. Psychiatry. 1999;60:477–484
  19. Chotai J, Kullgren G, Asberg M. CSF monoamine metabolites in relation to the diagnostic interview for borderline patients (DIB). Neuropsychobiology. 1998;38:207–212
  20. Cremniter D, Jamain S, Kollenbach K, Alvarez JC, Lecrubier Y, Gilton A, et al. CSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjects. Biol. Psychiatry. 1999;45:1572–1579
  21. Crow TJ, Cross AJ, Cooper SJ, Deakin JF, Ferrier IN, Johnson JA, et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression and suicides. Neuropsychopharmacology. 1984;23:1561–1569
  22. Degrell I, Nagy E. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid. Biol. Psychiatry. 1990;27:891–896
  23. Engstrom G, Alling C, Blennow K, Regnell G, Traskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur. Neuropsychopharmacol. 1999;9:399–405
  24. Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004;29:1029–1039Review
  25. Gabel S, Stadler J, Bjorn J, Schindledecker R, Bowden CL. Homovanillic acid and monoamine oxidase in sons of substance-abusing fathers: relationship to conduct disorder. J. Stud. Alcohol. 1995;56:135–139
  26. Gerra G, Zaimovic A, Moi G, Bussandri M, Delsignore R, Caccavari R, et al. Neuroendocrine correlates of antisocial personality disorder in abstinent heroin-dependent subjects. Addict Biol. 2003;8:23–32
  27. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  28. Jones JS, Stanley B, Mann JJ, Frances AJ, Guido JR, Traskman-Bendz L, et al. CSF 5-HIAA and HVA concentrations in elderly depressed patients who attempted suicide. Am. J. Psychiatry. 1990;147:1225–1227
  29. Koslow SH, Maas JW, Bowden CL, Davis JM, Hanin I, Javaid J. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Arch. Gen. Psychiatry. 1983;40:999–1010
  30. Mann JJ. Neurobiology of suicidal behaviour. Nat. Rev., Neurosci. 2003;4:819–828
  31. Melchitzky DS, Austin MC, Lewis DA. Chemical neuroanatomy of the primate brain. In:  Schatzberg AF,  Nemeroff CB editor. The American Psychiatric Publishing Textbook of Psychopharmacology. 3rd ed.. Washington, DC: Am Psychiatr Publ; 2000;p. 69–87
  32. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J. Affect. Disord. 1982;4:291–298
  33. Ohmori T, Arora RC, Meltzer HY. Serotonergic measures in suicide brain: the concentration of 5-HIAA, HVA, and tryptophan in frontal cortex of suicide victims. Biol. Psychiatry. 1992;32:57–71
  34. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol. Rep. 1962;10:799–812
  35. Papeschi R, Sourkes TL, Poirier LJ, Boucher R. On the intracerebral origin of homovanillic acid of the cerebrospinal fluid of experimental animals. Brain Res. 1971;28:527–533
  36. Pitchot W, Hansenne M, Moreno AG, Ansseau M. Suicidal behavior and growth hormone response to apomorphine test. Biol. Psychiatry. 1992;31:1213–1219
  37. Pitchot W, Hansenne M, Gonzalez Moreno A, Pinto E, Reggers J, Fuchs S, et al. Reduced dopamine function in depressed patients is related to suicidal behavior but not its lethality. Psychoneuroendocrinology. 2001;26:689–696
  38. Pitchot W, Reggers J, Pinto E, Hansenne M, Ansseau M. Catecholamine and HPA axis dysfunction in depression: relationship with suicidal behavior. Neuropsychobiology. 2003;47:152–157
  39. Post RM, Goodwin FK. Approaches to brain amines in psychiatric patients: a reevaluation of cerebrospinal fluid studies. In:  Iversen LL,  Iversen SD,  Snyder SH editor. Handbook of Psychopharmacology. Volume 13: Biology of Mood and Antianxiety Drugs. New York: Plenum Press; 1978;p. 147–185
  40. Rahe RH. Epidemiological studies of life change and illness. Int. J. Psychiatry Med. 1975;6:133–146
  41. Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS. CSF amine metabolites in depression. Biol. Psychiatry. 1992;31:112–118
  42. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J. Clin. Psychiatry. 2002;63:241–244
  43. Rosmond R, Rankinen T, Chagnon M, Perusse L, Chagnon YC, Bouchard C, et al. Polymorphism in exon 6 of the dopamine D(2) receptor gene (DRD2) is associated with elevated blood pressure and personality disorders in men. J. Hum. Hypertens. 2001;15:553–558
  44. Roy A, Agren H, Pickar D, Linnoila M, Doran AR, Cutler NR, et al. Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am. J. Psychiatry. 1986;143:1539–1545
  45. Roy A, De Jong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Arch. Gen. Psychiatry. 1989;46:609–612
  46. Scheinin M, Chang WH, Kirk KL, Linnoila M. Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. Anal. Biochem. 1983;131:246–253
  47. Schulz SC, Schulz PM, Dommisse C, Hamer RM, Blackard WG, Narasimhachari N, et al. Amphetamine response in borderline patients. Psychiatry Res. 1985;15:97–108
  48. Sher L, Mann JJ. Neurobiology of suicide. In:  Soares JC,  Gershon S editor. Textbook of Medical Psychiatry. NY: Marcel Dekker; 2003;p. 701–711
  49. Sher L, Oquendo MA, Li S, Huang Y, Grunebaum MF, Burke AK, et al. Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism. Neuropsychopharmacology. 2003;28:1712–1719
  50. Sher L, Oquendo MA, Li S, Burke AK, Grunebaum MF, Zalsman G, et al. Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid post-traumatic stress disorder. Eur. Neuropsychopharmacol. 2005;15:203–209
  51. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am. J. Psychiatry. 2004;161:398–413
  52. Siever LJ, Amin F, Coccaro EF, Bernstein D, Kavoussi RJ, Kalus O, et al. Plasma homovanillic acid in schizotypal personality disorder. Am. J. Psychiatry. 1991;148:1246–1248
  53. Siever LJ, Amin F, Coccaro EF, Trestman R, Silverman J, Horvath TB, et al CSF homovanillic acid in schizotypal personality disorder. Am. J. Psychiatry. 1993;150:149–151
  54. Soderstrom H, Blennow K, Manhem A, Forsman A. CSF studies in violent offenders: I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J. Neural Transm. 2001;108:869–878
  55. Stanley M, Traskman-Bendz L, Dorovini-Zis K. Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci. 1985;37:1279–1286
  56. Stuerenburg HJ, Ganzer S, Muller-Thomsen T. 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. Neuro Endocrinol. Lett. 2004;25:435–437
  57. Szigethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J. Clin. Psychopharmacol. 1997;17:326–327
  58. Traskman L, Asberg M, Bertilsson L, Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry. 1981;38:631–636
  59. Traskman-Bendz L, Alling C, Alsen M, Regnell G, Simonsson P, Ohman R. The role of monoamines in suicidal behavior. Acta Psychiatr. Scand. 1993;371(Suppl.):45–47
  60. Van Goozen SH, Matthys W, Cohen-Kettenis PT, Westenberg H, Van Engeland H. Plasma monoamine metabolites and aggression: two studies of normal and oppositional defiant disorder children. Eur. Neuropsychopharmacol. 1999;9:141–147
  61. Vanyukov MM, Moss HB, Kaplan BB, Kirillova GP, Tarter RE. Antisociality, substance dependence, and the DRD5 gene: a preliminary study. Am. J. Med. Genet. 2000;96:654–658
  62. Vestergaard P, Sorensen T, Hoppe E, Rafaelsen OJ, Yates CM, Nicolaou N. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr. Scand. 1978;58:88–96
  63. Westenberg HG, Verhoeven WM. CSF monoamine metabolites in patients and controls: support for a bimodal distribution in major affective disorders. Acta Psychiatr. Scand. 1988;78:541–549

PII: S0165-0327(05)00292-2

doi: 10.1016/j.jad.2005.10.002

Journal of Affective Disorders
Volume 90, Issue 1 , Pages 83-89 , January 2006

Article Tools